<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907543</url>
  </required_header>
  <id_info>
    <org_study_id>R-09-025</org_study_id>
    <nct_id>NCT00907543</nct_id>
  </id_info>
  <brief_title>Quality of Life in Neoadjuvant Versus Adjuvant Therapy of Esophageal Cancer Treatment Trial</brief_title>
  <acronym>QUINTETT</acronym>
  <official_title>Prospective Randomized Phase III Trial Comparing Preoperative Chemoradiation Therapy (Cisplatin, 5-FU and Radiotherapy Followed by Surgery) to Surgery Followed by Postoperative Chemoradiation (Cisplatin, Epirubicin, 5-FU, Radiotherapy) for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard Malthaner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the results of preoperative chemotherapy and
      radiation followed by surgery to surgery followed by postoperative chemotherapy and radiation
      for esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to neo-adjuvant or adjuvant treatment. Quality of life
      questionnaires will be completed every 2 months up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life as assessed by FACT-E</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and morbidity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Preoperative chemotherapy/radiotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postoperative chemotherapy/radiotherapy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative treatment of chemotherapy and radiation</intervention_name>
    <description>Cisplatin + 5FU with concurrent radiation followed by surgery</description>
    <arm_group_label>Neoadjuvant Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Postoperative treatment of chemotherapy and radiation</intervention_name>
    <description>Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation</description>
    <arm_group_label>Adjuvant Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented squamous cell carcinoma or adenocarcinoma of the thoracic
             esophagus (&gt; 20 cm from the incisors) or gastroesophageal junction are included.

          -  No distant metastases (M0).

          -  Patients will be stratified by stage (clinical N0 versus clinical N1), and surgeon.

          -  Patients with tumours within 3 cm distal spread into gastric cardia as detected by
             esophagogastroscopy.

          -  Resectable mediastinal nodes are eligible.

          -  No prior chemotherapy for this malignancy.

          -  No prior radiotherapy that would overlap the field(s) treated in this study.

          -  Patients with other malignancies are eligible only if &gt; 5 years without evidence of
             disease or completely resected or treated non-melanoma skin cancer.

          -  Age &gt; 18 years and able to tolerate tri-modality therapy at the discretion of the
             treating thoracic surgeon, medical and radiation oncologists. Tumours must be
             resectable after assessment by the thoracic surgeon.

        Exclusion Criteria:

          -  Cancers of the cervical esophagus (&lt; 20 cm are excluded).

          -  Tumours that have &gt; 3 cm of spread into cardia of the stomach are considered gastric
             cancers and are ineligible.

          -  Patients with biopsy (by endoscopic ultrasound, laparoscopy, or laparotomy ) proven
             metastatic supraclavicular nodes are ineligible.

          -  Patients with biopsy proven metastatic celiac nodes are ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Malthaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deb Lewis, BSc</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>75685</phone_ext>
    <email>deb.lewis@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Malthaner, MD</last_name>
      <phone>519-667-6835</phone>
      <email>richard.malthaner@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Deb Lewis, BSc</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>75685</phone_ext>
      <email>deb.lewis@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Malthaner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Richard Malthaner</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>esophageal carcinoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiation</keyword>
  <keyword>surgery</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

